Shares of LifeStance Health Group, Inc. (NASDAQ: LFST) are soaring 16.84% in Thursday's pre-market trading session following the release of better-than-expected third-quarter 2025 financial results and raised full-year guidance.

The outpatient mental healthcare provider reported Q3 revenue of $363.8 million, a 16% increase year-over-year, surpassing analyst expectations of $355.6 million. LifeStance achieved a net income of $1.1 million, marking a significant turnaround from the $6.0 million loss in the same period last year. Adjusted EBITDA rose 31% to $40.2 million, beating estimates of $35.16 million.

The strong performance was driven by a 17% increase in visit volumes, attributed to net clinician growth and improved productivity. LifeStance's clinician base grew 11% to 7,996, contributing to the revenue and visit volume increases. In light of these results, the company reiterated its full-year 2025 revenue guidance of $1.41 billion to $1.43 billion and raised its Adjusted EBITDA expectations to $146 million to $152 million. The positive outlook and improved operational efficiency have clearly resonated with investors, leading to the significant pre-market stock price jump.